biotie therapies finnish biotechnology pharmaceutics company acquired acorda therapeutics january companys research development focused drugs neurodegenerative psychiatric disorders like parkinsons disease alzheimers disease cognitive disorders alcohol drug dependence post traumatic stress disorder inflammatory fibrotic liver disease companys headquarters turku western finland listed nasdaq omx helsinki biotie therapies formed merger biotie therapies corp incorporated oy contral pharma ltd carbion inc year biotie therapies acquired german pharmaceutical discovery development company elbion gmbh radebeul biotie therapies preclinical assets transferred new company biocrea gmbh biotie become minority shareholder biotie acquired pharmaceutical company company partnering agreements h lundbeck january acorda therapeutics acquired biotie therapies companys advanced product nalmefene treatment alcoholism bioties partner h lundbeck received european marketing authorization european commission february lundbeck expects launch selincro first markets middle studies shown nalmefene ability significantly limit patients average alcohol intake number days intake five units alcohol drug works removing patients desire drink thereby controlling limiting intake alcohol drug used tablet form taken according need according company novel approach alcohol dependency treatment existing treatments aimed keeping patient drinking drugs taken continuously longer period also called tozadenant developed potential treatment parkinsons disease cns orally administered potent selective inhibitor adenosine receptor january company acquired acorda therapeutics november company announced discontinuation agent following death patients enrolled tozadenant phase iii trial agranulocytosis associated severe adverse events possibly related vascular adhesion monoclonal antibody intended treatment inflammatory diseases currently phase clinical trials rheumatoid arthritis patients according company inhibiting reduces inflammation regulating migration leukocytes white blood cells inflamed tissues pathological accumulation white blood cells tissue common feature many autoimmune diseases rheumatoid arthritis ulcerative colitis psoriasis also called nepicastat treatment cocaine dependency post traumatic stress disorder ptsd orally administered potent selective inhibitor enzyme dopamine Î²hydroxylase ronomilast inhibitor chronic inflammatory disorders small molecule inhibitor product developed treatment chronic obstructive pulmonary disease copd data preclinical early clinical trials indicates product good safety profile biotie process planning phase trial copd patients also seeking partner latestage development httpsenwikipediaorgwikibiotietherapies